+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 45 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying children aged 10 to 14 years who have a retrognathic mandible, a condition where the lower jaw is positioned backward. The trial aims to evaluate how functional appliance therapy using the Twin Block device affects 3D craniodentofacial features and reported sleep-related breathing disorders. This research also includes assessing the impact of the therapy on upper airway dimensions and sleep problems, which are important for overall child growth and development. Participants will receive the Twin Block functional appliance proposed after diagnostics, which they will wear for about one year. Three-dimensional facial scans will be taken before treatment, including at rest and with the mandible moved forward using the Fraenkel maneuver, as well as after the treatment ends. Caregivers will complete the Pediatric Sleep Questionnaire PSQ before and after treatment to evaluate perceived changes in sleep-related breathing issues. Additionally, lateral cephalogram X-rays will be taken from enrollment to the end of treatment to support the assessment. During the study, children will undergo detailed facial scans and X-rays to monitor changes in their facial structure and airway. Caregivers will provide input through questionnaires to assess sleep breathing problems. Researchers will compare initial scans and predicted treatment outcomes with actual results to evaluate therapy effectiveness. The total participation period is approximately one year, during which the team will closely observe facial growth, airway changes, and sleep-related symptoms to understand the therapys influence.

Age: 10Years - 14YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
S

Actively Recruiting

Many premature newborns have trouble breathing after birth and receive support with a breathing machine called nasal continuous positive airway pressure NCPAP. When their breathing worsens despite NCPAP, they may be treated with surfactant medication inserted into the windpipe using either a ventilation tube or a thin catheter. This research is studying the use of video laryngoscopes, which have a camera and display the airway on a screen, compared to standard direct laryngoscopes that require doctors to look directly into the babys mouth to insert the tube or catheter. The study aims to see if video laryngoscopy improves the success rate of inserting the thin catheter on the first attempt without causing drops in oxygen or heart rate. The study observes infants who need a thin endotracheal catheter inserted for surfactant administration. It compares two approaches using a video laryngoscope versus a direct laryngoscope during the insertion. This is done across multiple hospitals, each switching from direct to video laryngoscopy over time. The study does not assign which method is used but records which laryngoscope was used for each insertion attempt to compare outcomes. The main focus is on successful first attempts without physiologic instability, as well as secondary measures like number of attempts, duration, oxygen levels, heart rate, and any complications. Participants are newborn infants up to 28 days old who require thin catheter insertion for surfactant treatment and whose parents have consented to share data. Researchers will collect detailed information during and after the insertion attempt, including heart rate, oxygen saturation, duration of the procedure, and any adverse events such as oral trauma or need for chest compressions. Data will be analyzed to evaluate the success and safety of using video versus direct laryngoscopy. The total participation time depends on when the catheter insertion is performed and the follow-up assessments within 72 hours after the procedure.

Age: 0Minutes - 28DaysAll Genders
16 locations
R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
E

Actively Recruiting

Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.

Age: 8Years - 18YearsAll GendersPhase 3
121 locations
C

Actively Recruiting

Many newborn babies experience breathing difficulties that require intubation, a procedure where a tube is inserted into the windpipe to help with breathing support. This trial compares two methods used by doctors to perform intubation the traditional direct laryngoscopy DL, where doctors look directly into the babys mouth with a standard laryngoscope, and video laryngoscopy VL, which uses a camera and screen to view the windpipe. The study aims to determine if VL leads to more successful first attempts without causing drops in oxygen levels or heart rate compared to DL. The trial uses a stepped-wedge cluster randomized design across multiple hospitals. Initially, each hospital uses the standard DL method for intubation. At randomly assigned intervals, hospitals switch to using the VL device, the C-MAC video laryngoscope, which includes a monitor and special blades. Doctors receive training and practice with this device before switching. Other intubation practices, such as drug use and supplemental oxygen, remain the same throughout the study. Participants in the trial are newborn infants undergoing intubation. Researchers will collect information about intubation attempts, including success rates, oxygen levels, heart rates, and any complications like oral trauma or need for chest compressions. The main outcome is whether babies are successfully intubated on the first try without physiological instability within five minutes. Additional measures include procedure time, number of attempts, and adverse events. Data will be compared between the periods using DL and VL to assess effectiveness and safety over the course of the study, which lasts until August 2026.

Age: 0Minutes - 1MonthAll GendersPhase Not Applicable
17 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
S

Actively Recruiting

Researchers are evaluating whether combining vedolizumab and upadacitinib, called dual targeted therapy DTT, reduces bowel inflammation and ulcers more effectively than vedolizumab alone in adults with moderately to severely active Crohns Disease CD. The study also compares the safety and effectiveness of these treatments. This Phase 3b trial is conducted worldwide and sponsored by Takeda, enrolling about 396 participants. Participants are randomly assigned to receive either vedolizumab with upadacitinib or vedolizumab with a placebo for 12 weeks during the Induction Phase. Vedolizumab is given as a 300 mg intravenous infusion at Weeks 0, 2, 6, and 10 upadacitinib or placebo is taken daily by mouth. Those who respond to treatment at Week 12 will continue with vedolizumab alone every 8 weeks for 40 weeks in the Maintenance Phase. Vedolizumab dosing frequency may increase to every 4 weeks if needed. During the approximately 70-week study, participants visit the clinic 15 times for assessments including clinical evaluations, endoscopic exams, and patient-reported outcomes. Researchers measure clinical remission, endoscopic response, and safety outcomes at Week 12 and Week 52. There is also an 18-week safety follow-up after the maintenance period to monitor participants health.

Age: 18Years - 65YearsAll GendersPhase 3
138 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations

1-10 of 45

1